Patents by Inventor Jan Kitajewski
Jan Kitajewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11026996Abstract: This invention provides a fusion protein, the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids in: (a) an extracellular domain of a human Notch1 receptor protein, followed by (b) an Fc portion of an antibody, wherein the extracellular domain of the human Notch1 receptor protein (i) commences with the amino acid present at the N-terminus of EGF-like repeat 10 and (ii) extends to and includes the C-terminal amino acid of EGF-like repeat 18 or 20. Also provided is a composition comprising the any of the fusion proteins of this invention and a pharmaceutically acceptable carrier, a method of treating a subject suffering from age-related macular degeneration (AMD), diabetic retinopathy, or cancer which comprises administering to the subject any of the compositions of this invention in an amount effective to treat the subject's cancer.Type: GrantFiled: May 25, 2017Date of Patent: June 8, 2021Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jan Kitajewski, Reyhaan Ali Chaudhri
-
Publication number: 20190183975Abstract: This invention provides a fusion protein, the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids in: (a) an extracellular domain of a human Notch1 receptor protein, followed by (b) an Fc portion of an antibody, wherein the extracellular domain of the human Notch1 receptor protein (i) commences with the amino acid present at the N-terminus of EGF-like repeat 10 and (ii) extends to and includes the C-terminal amino acid of EGF-like repeat 18 or 20. Also provided is a composition comprising the any of the fusion proteins of this invention and a pharmaceutically acceptable carrier, a method of treating a subject suffering from age-related macular degeneration (AMD), diabetic retinopathy, or cancer which comprises administering to the subject any of the compositions of this invention in an amount effective to treat the subject's cancer.Type: ApplicationFiled: May 25, 2017Publication date: June 20, 2019Applicant: The Trustees of Columbia University in the City of New YorkInventors: Jan Kitajewski, Reyhaan Ali Chaudhri
-
Patent number: 10227399Abstract: Provided herein are Notch1 fusion proteins. These fusion proteins comprise consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of the amino acids in an extracellular domain of a human Notch1 receptor protein and an Fc portion of an antibody. The amino acid sequence of the extracellular domain (ECD) of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of EGF-like repeat 10 and extends at least through the C-terminal amino acid of EGF-like repeat 23. The N-terminal portion of the ECD of the human Notch1 receptor protein may extend up to the C-terminal amino acid of EGF-like repeat 24 or may extend up to the C-terminal amino acid of EGF-like repeat 36. Compositions of these fusion proteins are also provided. Also provided are methods of treating age-related macular degeneration (AMD), diabetic retinopathy and cancer using the fusion proteins described herein.Type: GrantFiled: July 5, 2017Date of Patent: March 12, 2019Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jan Kitajewski, Carrie Shawber, Thaned Kangsamaksin
-
Publication number: 20180303901Abstract: The present invention provides a method of treating a subject suffering from a fatty liver disease which comprises administering to the subject a Notch decoy protein or Jagged inhibitor in an amount effective to treat the subject's fatty liver disease. The present invention provides a composition comprising a pharmaceutically acceptable carrier and an amount of a Notch decoy protein or Jagged inhibitor effective to treat a fatty liver disease. The present invention provides a package comprising: (a) the pharmaceutical composition of the invention; and (b) instructions for using the pharmaceutical composition of step (a) to treat the fatty liver disease.Type: ApplicationFiled: May 10, 2018Publication date: October 25, 2018Applicant: The Trustees of Columbia University in the City of New YorkInventors: Utpal Pajvani, Jan Kitajewski
-
Publication number: 20170306006Abstract: Provided herein are Notch1 fusion proteins. These fusion proteins comprise consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of the amino acids in an extracellular domain of a human Notch1 receptor protein and an Fc portion of an antibody. The amino acid sequence of the extracellular domain (ECD) of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of EGF-like repeat 10 and extends at least through the C-terminal amino acid of EGF-like repeat 23. The N-terminal portion of the ECD of the human Notch1 receptor protein may extend up to the C-terminal amino acid of EGF-like repeat 24 or may extend up to the C-terminal amino acid of EGF-like repeat 36. Compositions of these fusion proteins are also provided. Also provided are methods of treating age-related macular degeneration (AMD), diabetic retinopathy and cancer using the fusion proteins described herein.Type: ApplicationFiled: July 5, 2017Publication date: October 26, 2017Applicant: The Trustees of Columbia University in the City of New YorkInventors: Jan Kitajewski, Carrie Shawber, Thaned Kangsamaksin
-
Patent number: 9738708Abstract: Provided herein are Notch1 fusion proteins. These fusion proteins comprise consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of the amino acids in an extracellular domain of a human Notch1 receptor protein and an Fc portion of an antibody. The amino acid sequence of the extracellular domain (ECD) of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of BGF-like repeat 10 and extends at least through the C-terminal amino acid of EGF-like repeat 23. The N-terminal portion of the ECD of the human Notch1 receptor protein may extend up to the C-terminal amino acid of EGF-like repeat 24 or may extend up to the C-terminal amino acid of EGF-like repeat 36. Compositions of these fusion proteins are also provided. Also provided are methods of treating age-related macular degeneration (AND), diabetic retinopathy and cancer using the fusion proteins described herein.Type: GrantFiled: October 4, 2012Date of Patent: August 22, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jan Kitajewski, Carrie Shawber, Thaned Kangsamaksin
-
Patent number: 9475855Abstract: This invention provides a fusion protein comprising a signal peptide, EGF repeats 1-X of the extracellular domain of human Notch3 receptor protein wherein X is any integer from 12 to 34, and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder.Type: GrantFiled: August 21, 2009Date of Patent: October 25, 2016Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jan Kitajewski, Carrie Shawber
-
Publication number: 20160115217Abstract: This invention provides a fusion protein comprising a signal peptide, an extracellular domain of human Notch receptor protein and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder.Type: ApplicationFiled: September 3, 2015Publication date: April 28, 2016Applicant: The Trustees of Columbia University in the City of New YorkInventors: Jan Kitajewski, Carrie Shawber
-
Publication number: 20160030513Abstract: The present invention provides a method of treating a subject suffering from a fatty liver disease which comprises administering to the subject a Notch decoy protein or Jagged inhibitor in an amount effective to treat the subject's fatty liver disease. The present invention provides a composition comprising a pharmaceutically acceptable carrier and an amount of a Notch decoy protein or Jagged inhibitor effective to treat a fatty liver disease. The present invention provides a package comprising: (a) the pharmaceutical composition of the invention and (b) instructions for using the pharmaceutical composition of step (a) to treat the fatty liver disease.Type: ApplicationFiled: July 30, 2015Publication date: February 4, 2016Applicant: The Trustees of Columbia University in the City of New YorkInventors: Utpal Pajvani, Jan Kitajewski
-
Publication number: 20150329615Abstract: This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide.Type: ApplicationFiled: March 25, 2015Publication date: November 19, 2015Applicant: The Trustees of Columbia University in the City of New YorkInventors: Jan Kitajewski, Carrie Shawber, Yasuhiro Funahashi
-
Patent number: 9127085Abstract: This invention provides a fusion protein comprising a single peptide, an extracellular domain of human Notch receptor protein and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder.Type: GrantFiled: August 22, 2008Date of Patent: September 8, 2015Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jan Kitajewski, Carrie Shawber
-
Patent number: 8993725Abstract: This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide.Type: GrantFiled: January 21, 2010Date of Patent: March 31, 2015Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jan Kitajewski, Carrie Shawber, Yasuhiro Funahashi
-
Publication number: 20140271643Abstract: Provided herein are Notch1 fusion proteins. These fusion proteins comprise consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of the amino acids in an extracellular domain of a human Notch1 receptor protein and an Fc portion of an antibody. The amino acid sequence of the extracellular domain (ECD) of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of EGF-like repeat 10 and extends at least through the C-terminal amino acid of EGF-like repeat 23. The N-terminal portion of the ECD of the human Notch1 receptor protein may extend up to the C-terminal amino acid of EGF-like repeat 24 or may extend up to the C-terminal amino acid of EGF-like repeat 36. Compositions of these fusion proteins are also provided. Also provided are methods of treating age-related macular degeneration (AMD), diabetic retinopathy and cancer using the fusion proteins described herein.Type: ApplicationFiled: October 4, 2012Publication date: September 18, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventors: Jan Kitajewski, Carrie Shawber, Thaned Kangsamaksin
-
Publication number: 20110223183Abstract: This invention provides a fusion protein comprising a signal peptide, EGF repeats 1-X of the extracellular domain of human Notch3 receptor protein wherein X is any integer from 12 to 34, and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder.Type: ApplicationFiled: August 21, 2009Publication date: September 15, 2011Inventors: Jan Kitajewski, Carrie Shawber
-
Publication number: 20100273990Abstract: This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide.Type: ApplicationFiled: January 21, 2010Publication date: October 28, 2010Inventors: Jan Kitajewski, Carrie Shawber, Yasuhiro Funahashi
-
Patent number: 7662919Abstract: This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide.Type: GrantFiled: April 26, 2005Date of Patent: February 16, 2010Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jan Kitajewski, Carrie Shawber, Yasuhiro Funahashi
-
Publication number: 20060030694Abstract: This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide.Type: ApplicationFiled: April 26, 2005Publication date: February 9, 2006Inventors: Jan Kitajewski, Carrie Shawber, Yasuhiro Funahashi
-
Patent number: 6379925Abstract: This invention provides methods of modulating angiogenesis, including promoting or inhibiting angiogenesis, e.g., in connection with treating abnormalities including hemangiomas, hemangiosarcomas, Kaposi's Sarcoma, ischemic disorders, and wounds. These methods involve administration of compounds that are selective agonists or antagonists of Notch4 protein. In addition, this invention provides an isolated nucleic acid molecule encoding a Notch4, an isolated Notch4 protein, vectors comprising an isolated nucleic acid molecule encoding a Notch4 protein, cells comprising such vectors, antibodies directed to Notch4 protein, nucleic acid probes useful for detecting nucleic acids encoding Notch4 protein, and antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes Notch4 protein.Type: GrantFiled: December 20, 1999Date of Patent: April 30, 2002Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jan Kitajewski, Hendrik Uyttendaele